Antengene will receive ~$27.71M up front incl. $13.85M upon signing and is eligible for ~$13.85M in remaining up front & ~$74.18M in milestones
Antengene will be responsible to continue to record revenues from sales of Xpovio in the mainland of China and lead the research and development, regulatory approvals and affairs, product supply, and distribution of Xpovio. Hansoh Pharma will be exclusively responsible for the commercialization of Xpovio in mainland of China & charge a service fee to Antengene
The sNDA of Xpovio as monotx. is expected to be submitted in Q3’23 for r/r DLBCL & in combination with adult patients for MM who have received one prior therapy in H1’24
Ref: PR Newswire | Image: Antengene
Related News:- Karyopharm and Menarini Receive MHRA’s Marketing Authorization of Nexpovio (selinexor) for the Treatment of Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
